PROSTATE CANCER with the support of Bayer
- Which second generation hormonal treatment to choose in mHSPC? A personalized approach
- Metachronous low volume mHSPC: intermitent, doublet or triplet therapy?
- Strategy to delay systemic treatments with SBRT in prostate cancer